Item 7.01 — Regulation FD Disclosure

Voluntarily-disclosed material information under Regulation FD (e.g., investor presentation, conference talk).

is furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained herein is not incorporated by reference in any filing of Dexcom under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof except as shall be expressly set forth by specific reference in such a filing.Statement Regarding Use of Non-GAAP Financial MeasuresThis Form 8-K includes non-GAAP financial measures.

Item 8.01 — Other Events

A material event not falling under any other 8-K item.

On May 14, 2026, Dexcom announced that its Board of Directors authorized and approved a share repurchase program of up to $1.0 billion of Dexcom’s outstanding common stock, par value $0.001 per share (“Common Stock”), with a repurchase period ending no later than June 30, 2027 (the “Share Repurchase Program”). In connection with the approval of the Share Repurchase Program, the Board of Directors terminated its existing share repurchase program, of which $250.0 million remained available to be repurchased under the program.Repurchases of Common Stock under the Share Repurchase Program may be made from time to time in the open market, in privately negotiated transactions or by other methods,…